• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Insmed Incorporated

    5/14/25 5:35:25 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INSM alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001604019
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    INSMED Inc
    SEC File Number
    000-30739
    Address of Issuer
    700 US HIGHWAY 202/206
    BRIDGEWATER
    NEW JERSEY
    08807
    Phone
    908-977-9900
    Name of Person for Whose Account the Securities are To Be Sold
    Bonstein Sara
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Merrill Lynch
    1800 K ST NW
    Suite 800
    Washington � DC � 20006
    1634107206.0018213882305/14/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/12/2025Stock Plan ActivityIssuerCheckbox not checked163405/12/2025n/a

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Sara Bonstein
    700 US Highway 202/206
    Bridgewater � NJ � 08807
    Common05/13/20258870601474.00
    Sara Bonstein
    700 US Highway 202/206
    Bridgewater � NJ � 08807
    Common02/18/2025183221470887.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/14/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Sara Bonstein

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $INSM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INSM

    DatePrice TargetRatingAnalyst
    5/13/2025$105.00Buy
    Jefferies
    2/25/2025$100.00Outperform
    RBC Capital Mkts
    4/23/2024$48.00Buy
    Truist
    2/15/2024$42.00Outperform
    Wolfe Research
    12/8/2023$55.00Overweight
    Wells Fargo
    11/20/2023$36.00Overweight
    JP Morgan
    7/26/2023$50.00Buy
    Guggenheim
    12/9/2022$28.00Buy
    Mizuho
    More analyst ratings

    $INSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Bonstein Sara was granted 6,508 shares, increasing direct ownership by 6% to 114,867 units (SEC Form 4)

      4 - INSMED Inc (0001104506) (Issuer)

      5/19/25 5:06:31 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Adsett Roger was granted 6,508 shares, increasing direct ownership by 5% to 143,183 units (SEC Form 4)

      4 - INSMED Inc (0001104506) (Issuer)

      5/19/25 5:06:18 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief People Strategy Officer Schaeffer Orlov S Nicole was granted 5,578 shares, increasing direct ownership by 5% to 120,221 units (SEC Form 4)

      4 - INSMED Inc (0001104506) (Issuer)

      5/19/25 5:06:06 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

      —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH Completed; Topline Data Expected in June 2025— —Enrollment Completed for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP; Topline Data Anticipated By the End of 2025— —MAA Filings for Brensocatib in Patients with Bronchiectasis Accepted by EMA and MHRA— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance Range of $405 Million to $425 Million,

      5/8/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed To Present at the BofA Securities 2025 Health Care Conference

      BRIDGEWATER, N.J., April 29, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the BofA Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025, at 2:20 p.m. PT. This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events. About Insmed Insmed Incorporated is a people-first global biopharm

      4/29/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

      BRIDGEWATER, N.J., April 24, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has called all $569.5 million aggregate principal amount of its remaining outstanding 0.75% Convertible Senior Notes Due 2028 (the "Notes") (CUSIP No. 457669AB5) for redemption on June 6, 2025 (the "Redemption Date"). Insmed is redeeming the Notes as permitted under Section 11.03 of the indenture governing the Notes (the "Indenture"). Redemption Process The redemption price will be payable on the Redemption Date in cash and

      4/24/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    Leadership Updates

    Live Leadership Updates

    See more
    • Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

      —Insmed Leads Science Top Employers List for Fourth Year in a Row— BRIDGEWATER, N.J., Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2024 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics. "It is a tremendous honor to have been named the No. 1 employer in Science's annual survey for the fourth consecutive year

      10/24/24 4:05:00 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Names Drayton Wise Chief Commercial Officer

      BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibilities leading the global ARIKAYCE® (amikacin liposome inhalation suspension) franchise and U.S. commercial activities, Mr. Wise will assume responsibility for all of Insmed's global commercial functions. Mr. Wise will also serve as a member of Insmed's Executive Committee. "We are thrilled to promote Drayton to Chief Commercial Officer at this critical inflecti

      5/23/22 8:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $INSM
    Financials

    Live finance-specific insights

    See more

    $INSM
    SEC Filings

    See more

    $INSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $INSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Amendment: SEC Form SC 13G/A filed by Insmed Incorporated

      SC 13G/A - INSMED Inc (0001104506) (Subject)

      11/14/24 1:22:37 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Insmed Incorporated

      SC 13G - INSMED Inc (0001104506) (Subject)

      9/3/24 5:22:55 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Insmed Incorporated (Amendment)

      SC 13G/A - INSMED Inc (0001104506) (Subject)

      2/16/24 5:43:57 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

      —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH Completed; Topline Data Expected in June 2025— —Enrollment Completed for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP; Topline Data Anticipated By the End of 2025— —MAA Filings for Brensocatib in Patients with Bronchiectasis Accepted by EMA and MHRA— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance Range of $405 Million to $425 Million,

      5/8/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

      BRIDGEWATER, N.J., April 23, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its first-quarter 2025 financial results on Thursday, May 8, 2025. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, May 8, 2025, to discuss financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code

      4/23/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

      —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper End of Full-Year 2024 Guidance Range— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance of $405 Million to $425 Million, Reflecting Double-Digit Growth Compared to 2024— —NDA for Brensocatib in Patients with Bronchiectasis Accepted by FDA and Granted Priority Review with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH, Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP, and Phase 3 ENCORE Study of ARIKAYCE Remain on Track for Topline Data

      2/20/25 7:00:00 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Insmed Incorporated

      S-8 - INSMED Inc (0001104506) (Filer)

      5/16/25 4:56:14 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insmed Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - INSMED Inc (0001104506) (Filer)

      5/16/25 4:37:46 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Insmed Incorporated

      144 - INSMED Inc (0001104506) (Subject)

      5/14/25 5:49:07 PM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Insmed with a new price target

      Jefferies initiated coverage of Insmed with a rating of Buy and set a new price target of $105.00

      5/13/25 9:43:52 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Insmed with a new price target

      RBC Capital Mkts initiated coverage of Insmed with a rating of Outperform and set a new price target of $100.00

      2/25/25 7:09:15 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist initiated coverage on Insmed with a new price target

      Truist initiated coverage of Insmed with a rating of Buy and set a new price target of $48.00

      4/23/24 6:29:24 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ARIKAYCE KIT issued to INSMED INC

      Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

      6/2/23 4:38:39 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ARIKAYCE KIT issued to INSMED INC

      Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

      2/13/23 4:39:32 AM ET
      $INSM
      Biotechnology: Pharmaceutical Preparations
      Health Care